Novartis will pay $150 million to license a cardiovascular drug from Carlsbad-based Ionis Pharmaceuticals, it was announced Feb. 25.
Ionis and its spinout Akcea Therapeutics will share the payment.
Novartis picked up the rights to Akcea-Apo(a)-LRx, a drug candidate intended for elevated levels of lipoprotein (a) that can’t be reduced by diet or exercise and that contribute to risks like blood clots. The large pharmaceutical will handle a phase 3 clinical study, and if the drug is approved, global commercialization.
Promising phase 2 clinical trial results laid the groundwork for the deal.
“We believe that this therapy has the potential to be a significant advance for millions of people affected by cardiovascular disease around the world,” said Paula Soteropoulos, chief executive officer at Akcea.
The drug was discovered by Ionis and co-developed by Akcea and Ionis. The $150 million will go to Akcea, which will pay Ionis $75 million in common stock.